American College of Clinical Pharmacy
      Search      Cart
         

BCOP Clinical Session -- Hide and Go Seek: Updates in the Management of Acute, Chronic, and Refractory Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

Monday, October 28, 2019 from 8:00 AM to 10:00 AM EST at 2nd Floor: Gramercy East

Available for 2.00 hours of CPE credit
Activity Number: 0217-9999-19-172-L01-P
Activity Type: An Application-Based Activity

The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists, approved by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and then must pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 17, 2019 at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 29, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be June 17, 2020.

Learning Objectives
1. Describe the mechanism of action of CTLA-4, PD-1, and PD-L1 inhibitors and how their differences contribute to their respective immune-related adverse event profile.
2. Evaluate the safety and efficacy data available for current FDA approved immunotherapy agents and treatment regimens.
3. Design a customized treatment plan for a patient presenting to the acute care inpatient service with a severe or life-threatening irAE.
4. Design a customized treatment plan for a patient presenting to an ambulatory outpatient clinic with a chronic or steroid refractory irAE.
5. Reccomend effective approaches to care coordination and survivorship planning for patients who experience irAE across a healthcare system.
Introduction
8:00 AM

Speakers
  • Eve-Michelle  Segal, Pharm.D., BCOPSpeaker: Eve-Michelle Segal, Pharm.D., BCOP
    Lead Clinical Pharmacist, University of Washington Medical Center/Seattle Cancer Care Allicance; Clinical Instructor, University of Washington School of Pharmacy, Seattle< Washington
      View Biography

Immunotherapy Agents in Oncology
8:05 AM

Speakers
  • Joseph S. Bubalo, Pharm.D., BCPS, BCOPSpeaker: Joseph S. Bubalo, Pharm.D., BCPS, BCOP
    Oncology Clinical Pharmacy Specialist, OHSU Hospital and Clinics, Portland, Oregon
      View Biography

Differential Diagnosis and Treatment of Immune-related Adverse Effects in the Acute Care Setting
8:30 AM

Speakers
  • Speaker: Joseph S. Bubalo, Pharm.D., BCPS, BCOP
    Oncology Clinical Pharmacy Specialist, OHSU Hospital and Clinics, Portland, Oregon
      View Biography

Differential Diagnosis and Treatment of Immune-related Adverse Effects in the Ambulatory Care Setting
8:55 AM

Speakers
  • Carolyn J. Oxencis, Pharm.D., BCOPSpeaker: Carolyn J. Oxencis, Pharm.D., BCOP
    Hematology/Oncology Clinical Pharmacist, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin
      View Biography

Interprofession Collaboration to Develop irAE Treatment Algorithms and Survivorship Plans
9:20 AM

Speakers
  • Speaker: Carolyn J. Oxencis, Pharm.D., BCOP
    Hematology/Oncology Clinical Pharmacist, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin
      View Biography

Question and Answer
9:45 AM
Wrap-Up and Conclusions
9:55 AM